Finn
MIRM Biotechnology · Rare disease · Liver disease · Commercial biotech · Thesis updated November 8, 2026

LIVMARLI growth and new FOP launch fund a dense pipeline

01 Running thesis

Scaling commercial assets to fund pipeline bets

Mirum is evolving from a single rare liver story into a broader rare disease franchise. Its core drug, LIVMARLI, treats severe itching tied to rare liver diseases. The bull case is simple. The company needs to keep finding more eligible patients, keep payers covering the drug, and use its commercial footprint to launch newly approved products like Atebrioz.

The commercial execution is strengthening. Management raised full year 2026 revenue guidance to between $715 million and $720 million, fueled by a reliable $10 million to $15 million quarterly step up in adult PFIC uptake for LIVMARLI. The company expanded its U.S. field team to about 60 people to reach more than 4,000 liver health care professionals.

The pipeline offers Mirum several ways to grow, creating an extremely dense catalyst path. Management is preparing for five regulatory submissions in the first half of 2027. These include NDAs for volixibat, a BLA for brelovitug in HDV, and label expansions for both Atebrioz and LIVMARLI. As these trials wrap up, management expects research spending to drop from half of revenue to around 10 percent by late 2027, opening a path to positive operating cash flow.

The bear case centers on execution risks across this busy schedule. Rare disease markets are small, and launches can stall if doctors do not adopt new therapies quickly. The volixibat delay in PSC highlights the ongoing regulatory risks involved in pushing five separate submissions through the FDA in a single half year.

Nov 2026▲Mirum raised full year 2026 revenue guidance to between $715 million and $720 million. Atebrioz launched for FOP, and management outlined a dense catalyst path with five regulatory submissions planned for the first half of 2027.
Aug 2026→Mirum raised previous full year 2026 revenue guidance based on LIVMARLI strength. However, the FDA recommended a Phase 3 trial for volixibat in PSC, delaying the NDA submission to the first half of 2027.
May 2026▲Mirum raised full year 2026 revenue guidance after strong demand across brands. Management also noted that operating cash flow is expected to turn positive in 2027.
May 2026▲Volixibat produced positive VISTAS Phase 2b topline results in PSC. The company also secured zilurgisertib commercial rights.
Feb 2026▲The Bluejay acquisition added brelovitug for chronic HDV infection. This moved Mirum further into viral hepatitis and established AZURE Phase 3 readouts for late 2026.
Nov 2025→Mirum posted a brief net income milestone in Q3 2025, but warned losses would likely continue in the near term as it funds trials and commercial work.
Aug 2025→The thesis stayed mostly intact. Mirum planned to start a Phase 2 trial of MRM-3379 in Fragile X syndrome in the fourth quarter of 2025.
May 2025▲Takeda received Japanese approval for LIVMARLI in ALGS and PFIC, adding to the international footprint. Management also provided firmer volixibat clinical timelines.
02 Business model

Selling scarce medicines to small markets

Mirum makes money by selling approved medicines for rare diseases. These are not mass market drugs. They are aimed at small patient groups where treatment options are limited and pricing can be high if insurers agree the drug provides value.

The company sells directly in the United States and some European countries. In other places, it uses partners and distributors. Takeda, for example, handles LIVMARLI in Japan under a licensing and supply agreement.

This model can be highly profitable once a medicine is approved. Sales teams can target a clear group of specialists, and a small number of diagnosed patients can still support large revenue. The weak point is that every single patient matters. If diagnosis, reimbursement, safety, or doctor education slips, growth can slow fast.

Mirum also acquires or licenses assets to widen its base. This strategy can speed growth, but it raises the bill for research, milestones, royalties, and commercial buildouts. The Bluejay deal brought brelovitug, while the Incyte agreement brought rights to commercialize zilurgisertib, which is now approved as Atebrioz.

03 Product portfolio

Approved drugs and pipeline options

Growth engine

LIVMARLI

Approved for cholestatic pruritus in Alagille syndrome and PFIC. It is Mirum's largest product, featuring steady quarterly growth in the adult PFIC market.

Growth engine

Atebrioz

Approved in September 2026 for fibrodysplasia ossificans progressiva in patients 12 and older. The U.S. launch commenced in October 2026.

Steady

Cholbam and Ctexli

Cholbam treats bile acid synthesis disorders, and Ctexli treats adults with CTX. Mirum groups these as bile acid medicines in its reporting.

Option

Volixibat

Advanced for PSC and PBC. Mirum plans to submit NDAs for this candidate in the first half of 2027 following regulatory negotiations.

Option

Brelovitug

Acquired via Bluejay Therapeutics, this candidate targets chronic hepatitis D virus. A BLA submission is targeted for the first half of 2027.

Option

MRM-3379

An oral CNS-penetrant PDE4D inhibitor for Fragile X syndrome. It expands Mirum beyond liver and bile acid disease into neurocognitive disorders.

04 Business segments

One segment, two major sales buckets

LIVMARLI product sales71%growing fast
Bile acid medicines product sales29%modest

Mirum manages the company as one operating segment. For Q1 2026 product sales, LIVMARLI produced $113.804 million and bile acid medicines produced $46.078 million, out of $159.882 million total product sales.

05 Risk factors

What could break the story

Adult PFIC launch slows

High impact · Medium odds

The 2026 guidance raise depends heavily on persistent LIVMARLI demand, including an estimated 2,000 adult PFIC patients. Mirum expanded its field team to reach adult liver care settings, but hiring sales representatives does not guarantee prescriptions. If adult hepatologists do not adopt LIVMARLI as expected, the primary growth story weakens.

We watchQuarterly LIVMARLI sales, guidance changes, and comments on adult PFIC prescriber growth.

Reimbursement or pricing pressure

High impact · Medium odds

Rare disease drugs depend on high prices and broad insurance coverage. Mirum must keep payers convinced that its approved medicines are worth covering. More denials, larger rebates, or tougher government pricing policies could reduce net sales even if patient demand stays high.

We watchNet product sales versus prescription demand, gross-to-net commentary, and payer access updates.

Pipeline execution bottleneck

High impact · Medium odds

A massive portion of future upside sits in the pipeline. Management plans five major regulatory submissions for the first half of 2027. Any manufacturing delays, data questions from the FDA, or simple execution hurdles could delay these timelines and hurt the stock.

We watchVolixibat NDA timing updates, brelovitug BLA progress, and Atebrioz label expansion filings.

Supply and channel concentration

Medium impact · Low odds

Mirum relies on a single third-party logistics provider and a single specialty pharmacy for all sales of approved medicines in the United States and Canada. That makes distribution simpler, but it creates a single point of failure. A service disruption could block patient access and hurt reported sales.

We watchAny filing disclosure about specialty pharmacy, distributor, or logistics disruption.
06 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Mirum Q3 2026 earnings transcript
  2. Mirum Q2 2026 earnings transcript
  3. Mirum Q1 2026 Form 10-Q
  4. Mirum 2025 Form 10-K
07 Explore the industry

Comparable Biotechnology companies

Companies near Mirum Pharmaceuticals, Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today